Skip to main content

Table 3 Post therapy

From: Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators

  n PR L-SD SD PD NE PDa
ADM/EPI + CPA 3     3   1
S1 3    3    1
PTX + BEV 23 5 1 9 5 3  
ERI 3 1    1 1 2
DTX 1     1   
EXE + EVE 1     1   
CPA 1     1   
None 1       
Pembrolizumab 1      1  
Rx to the whole brain 3 1   1 1   
  1. a: Progressive disease in induction therapy
  2. ADM doxorubicin, EPI epirubicin, CPA cyclophosphamide, PTX paclitaxel, BEV bevacizumab, ERI eribulin, DTX docetaxel, EXE exemestane, EVE everolimus, Rx radiation, PR partial response, L-SD long-lasting stable disease, SD stable disease, PD progressive disease, NE not evaluable